William Blair analyst Matt Phipps has maintained their bullish stance on CNTX stock, giving a Buy rating on October 27.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Matt Phipps’s rating is based on several promising developments within Context Therapeutics. The company recently shared preliminary data from its Phase Ia study of the CLDN6xCD3 T-cell engager, CTIM-76, which showed early signs of antitumor activity. Notably, a patient with platinum-resistant ovarian cancer demonstrated a RECIST response, indicating potential effectiveness of the treatment.
Additionally, the ongoing study has not encountered any severe cytokine release syndrome events or dose-limiting toxicities, suggesting a favorable safety profile. The absence of a maximum tolerated dose being reached further supports the potential for continued dose escalation. These factors collectively contribute to the positive outlook for Context Therapeutics, justifying the Buy rating.
In another report released on October 27, Piper Sandler also maintained a Buy rating on the stock with a $4.00 price target.